company background image
EYWN logo

bioMérieux DB:EYWN Stock Report

Last Price

€97.35

Market Cap

€11.4b

7D

-3.5%

1Y

0.6%

Updated

21 Nov, 2024

Data

Company Financials +

EYWN Stock Overview

Develops and markets in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. More details

EYWN fundamental analysis
Snowflake Score
Valuation4/6
Future Growth2/6
Past Performance4/6
Financial Health6/6
Dividends3/6

bioMérieux S.A. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for bioMérieux
Historical stock prices
Current Share Price€97.35
52 Week High€110.50
52 Week Low€88.90
Beta0.22
11 Month Change-6.75%
3 Month Change-5.94%
1 Year Change0.57%
33 Year Change-19.91%
5 Year Change16.66%
Change since IPO265.52%

Recent News & Updates

Recent updates

Shareholder Returns

EYWNDE Medical EquipmentDE Market
7D-3.5%-0.4%-0.4%
1Y0.6%-7.1%7.1%

Return vs Industry: EYWN exceeded the German Medical Equipment industry which returned -6.1% over the past year.

Return vs Market: EYWN underperformed the German Market which returned 7.8% over the past year.

Price Volatility

Is EYWN's price volatile compared to industry and market?
EYWN volatility
EYWN Average Weekly Movement3.7%
Medical Equipment Industry Average Movement5.2%
Market Average Movement4.8%
10% most volatile stocks in DE Market11.0%
10% least volatile stocks in DE Market2.4%

Stable Share Price: EYWN has not had significant price volatility in the past 3 months compared to the German market.

Volatility Over Time: EYWN's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
196313,696Pierre Bouludwww.biomerieux.com

bioMérieux S.A. develops and markets in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers CHROMID RANGE, a chromogen culture media; RAPIDEC CARBA NP biochemical test for the detection of carbapenemaseproducing bacteria; air, surface, and water monitoring systems; BACT/ALERT VIRTUO BACT/ALERT 3D, a blood sample culture system; BIOFIRE, a multiplex polymerase chain reaction (PCR) system; BIOFIRE SPOTFIRE Lowplex PCR point-of-care system; VITEK MS, a mass spectrometry system; VITEK 2, an automated Identification and antimicrobial susceptibility testing (AST) system; API RANGE standardized ID strips; VITEK REVEAL Rapid AST system; ETEST Gradient method on culture media; BIOMERIEUX EPISEQ CS whole genome sequencing solution for epidemiologic monitoring; and VIDASB·R·A·H·M·S PCTTM, a specific marker of severe bacterial infections/sepsis. It also provides Biomérieux vision suite, a software that provides actionable information to support diagnosis and clinical decision making; culture media and associated instruments; ARGENE Monoplex PCR tests; NUCLISENS ranges, a product for automation of the molecular biology laboratory and extraction; EMAG system For DNA and RNA extraction; ESTREAM, an automated preparation station for samples to process PCR tests; GENE-UP and VERIFLOW ranges for detection of microorganisms for the food industry.

bioMérieux S.A. Fundamentals Summary

How do bioMérieux's earnings and revenue compare to its market cap?
EYWN fundamental statistics
Market cap€11.39b
Earnings (TTM)€411.30m
Revenue (TTM)€3.81b

27.7x

P/E Ratio

3.0x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
EYWN income statement (TTM)
Revenue€3.81b
Cost of Revenue€1.69b
Gross Profit€2.12b
Other Expenses€1.71b
Earnings€411.30m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)3.49
Gross Margin55.72%
Net Profit Margin10.81%
Debt/Equity Ratio10.1%

How did EYWN perform over the long term?

See historical performance and comparison

Dividends

0.9%

Current Dividend Yield

24%

Payout Ratio